预约演示
更新于：2025-07-19
Argatroban
阿加曲班
更新于：2025-07-19
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (1996-04-16), |
最高研发阶段(中国)撤市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H38N6O6S |
InChIKeyAIEZTKLTLCMZIA-CZSXTPSTSA-N |
CAS号141396-28-3 |
关联
39
项与 阿加曲班 相关的临床试验NCT06442267
A Three-arm Randomized Controlled Non-inferiority Pilot Study Comparing Anticoagulation Strategies Using Unfractionated Heparin, Argatroban and Low-molecular-weight Heparin for Extracorporeal Membrane Oxygenation Support
NCT05226442
A Prospective Randomized Pilot Trial on Safety and Feasibility of Argatroban As Anticoagulant in Patients with Extracorporeal Membrane Oxygenation (ECMO)
EUCTR2021-001456-34-AT
A prospective randomized pilot trial on safety and feasibility of Argatroban as anticoagulant in patients with extracorporeal membrane oxygenation (ECMO)
100 项与 阿加曲班 相关的临床结果
登录后查看更多信息
100 项与 阿加曲班 相关的转化医学
登录后查看更多信息
100 项与 阿加曲班 相关的专利（医药）
登录后查看更多信息
1,606
项与 阿加曲班 相关的文献（医药）2025-07-01STROKE
Effect of Argatroban Plus Dual Antiplatelet in Branch Atherosclerosis Disease: A Randomized Clinical Trial.
Article
作者: Gong, Liang ; He, Lanying ; Sun, Rong ; Xu, Xuejun ; Zhao, Hongjian ; Yang, Juan ; Liu, Yinglin ; Li, Yuanyuan ; Wang, Jian ; Liu, Xindong ; Zhang, Bei ; Xu, Ronghua ; Wang, Huazedan ; Ding, Xin ; Xu, Jinghan
BACKGROUND:
Branch atherosclerosis disease (BAD) is prone to early neurological deterioration (END). The purpose of this study was to assess the efficacy and safety of argatroban plus dual antiplatelet therapy (DAPT) for preventing END in high-risk branch atherosclerosis disease patients.
METHODS:
This multicenter, open-label, blinded end point, randomized controlled trial including branch atherosclerosis disease patients with mild stroke (National Institutes of Health Stroke Scale score ≤5) was conducted at 4 centers in China from May 18, 2021 to February 8, 2023. Within 48 hours after symptom onset, patients were randomly assigned to receive argatroban plus DAPT or DAPT alone in a 1:1 ratio. The primary end points were the incidence of END (National Institutes of Health Stroke Scale score increase ≥2) within 7 days and excellent functional outcome (modified Rankin Scale score of 0 to 1) at 90 days.
RESULTS:
A total of 111 patients were randomized, with 11 excluded for specific reasons, resulting in 100 patients included in the modified intention-to-treat population. Among the 100 patients, 49 received argatroban plus DAPT and 51 received DAPT alone, 63 (63.0%) were men, and the median age was 64 (range, 55-74) years. END occurred in 20.4% (10/49) of the argatroban plus DAPT group and 47.1% (24/51) of the DAPT group (risk difference, 26.7% [95% CI, 14.1-39.2]; risk ratio, 2.31 [95% CI, 1.49-3.58]; P=0.006). At the 90-day follow-up, 87.8% (43/49) in the argatroban plus DAPT group and 68.6% (35/51) in the DAPT group achieved an excellent functional outcome (risk difference, -19.1% [95% CI, -30.3 to -8.0]; risk ratio, 0.78 [95% CI, 0.67-0.91]; P=0.025). There was 1 minor hemorrhage in each group.
CONCLUSIONS:
Argatroban plus DAPT is a safe and effective strategy to reduce END occurrence and improve 90-day functional outcome in high-risk branch atherosclerosis disease patients.
REGISTRATION:
URL: https://www.chictr.org.cn; Unique Identifier: ChiCTR21000 46487.
2025-06-01CNS Neuroscience & Therapeutics
Association Between Argatroban and Outcomes of Branch Atheromatous Disease: A Propensity‐Matched Analysis From MRI ‐Based Study
Article
作者: Hu, Haizhou ; Liu, Bin ; Li, Shengde ; Chen, Guofang ; Zhu, Yicheng ; Zhang, Ping ; Zhou, Lixin ; Bai, Hongying ; Peng, Bin ; Ni, Jun ; Zhou, Yaping
ABSTRACT:
Background and Purpose:
Argatroban is widely used for patients with acute branch atheromatous disease (BAD)‐related stroke, but its efficacy remains unclear. This study aims to evaluate its clinical outcomes in this patient population.
Methods:
A prospective, MRI‐based cohort (BAD‐study) was conducted across 20 hospitals in China from June 2021 to June 2023, enrolling patients aged 18–80 years with BAD‐related stroke within 72 h of onset. Patients were divided into two groups: Argatroban and non‐argatroban. The primary outcome was an excellent outcome, defined as a modified Rankin Scale (mRS) score of 0–1 at 90 days. Secondary outcomes included good outcome (mRS 0–2), mRS score, Barthel Index score at 90 days, and NIHSS score at 7 days. Logistic regression analyses were performed to assess the association between argatroban and outcomes after propensity score matching (PSM).
Results:
A total of 467 patients were included, with a median age of 60 years and a median NIHSS score of 4 at admission. Eighty‐six patients (18.4%) were in the argatroban group, and 381 patients (81.6%) were in the non‐argatroban group. After PSM, excellent outcomes occurred in 60.0% of the argatroban group and 64.2% of the non‐argatroban group (odds ratio [OR] = 0.84, 95% CI: 0.47–1.49, p = 0.542). Argatroban was not significantly associated with secondary outcomes and remained ineffective in sensitivity analyses.
Conclusion:
Argatroban was not associated with excellent outcome at 90 days in patients with acute BAD‐related stroke. Our study suggests that the risks and benefits of argatroban need reevaluation in patients with BAD‐related stroke.
2025-06-01Cureus Journal of Medical Science
Fondaparinux Failure in Heparin-Induced Thrombocytopenia With Acute Limb Ischemia: A Case Report and Literature Review.
Article
作者: Bowen, Adam ; Baraka, Dania ; Quasem, Khaleel ; Alshaikhli, Alfarooq ; Bayya, Maha
Heparin-induced thrombocytopenia (HIT), a prothrombotic disorder caused by heparin-dependent antibodies, is often treated with fondaparinux, generally yielding positive outcomes. A 69-year-old male with a history of stage IIIb small cell lung cancer developed severe HIT (platelet count nadir, 11 × 10⁹/L) after receiving heparin for stroke prophylaxis, complicated by deep vein thrombosis (DVT) and acute limb ischemia (ALI). Despite treatment with fondaparinux, thrombocytopenia secondary to HIT persisted, and his arterial thrombosis progressed, leading to urgent angioplasty and thrombectomy. This clinical course raised concerns for autoimmune HIT (aHIT) refractory to fondaparinux or potential fondaparinux cross-reactivity. The patient was transitioned to argatroban postoperatively, resulting in rapid platelet recovery and clinical improvement. Our case highlights the limitations of fondaparinux in select HIT cases, particularly when aHIT is suspected, and underscores the need for vigilance in monitoring for treatment failure. This report adds to emerging data on alternative anticoagulation strategies for refractory HIT, including the potential role of direct thrombin inhibitors in severe cases.
149
项与 阿加曲班 相关的新闻（医药）2025-06-23
·博瑞生物
临床2期临床3期临床结果临床1期
2025-06-15
·信狐药迅
2025-06-12
带量采购核酸药物申请上市蛋白降解靶向嵌合体细胞疗法
100 项与 阿加曲班 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肝素诱导的血小板减少伴血栓形成 | 日本 | 2008-07-16 | |
| 血栓形成 | 日本 | 2005-07-01 | |
| 肝素诱导血小板减少 | 丹麦 | 2005-03-01 | |
| 肝素诱导血小板减少 | 意大利 | 2005-03-01 | |
| 肝素诱导血小板减少 | 挪威 | 2005-03-01 | |
| 肝素诱导血小板减少 | 西班牙 | 2005-03-01 | |
| 肝素诱导血小板减少 | 瑞典 | 2005-03-01 | |
| 肝素诱导血小板减少 | 英国 | 2005-03-01 | |
| 动脉硬化闭塞症 | 中国 | 2002-08-02 | |
| 缺血性脑梗死 | 中国 | 2002-08-02 | |
| 血栓闭塞性血管炎 | 中国 | 2002-08-02 | |
| 血小板减少症 | 美国 | 2000-06-30 | |
| 抗凝血酶III缺乏症 | 日本 | 1996-04-16 | |
| 脑静脉血栓形成 | 日本 | 1996-04-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 不稳定型心绞痛 | 临床2期 | 比利时 | 2005-08-01 | |
| 不稳定型心绞痛 | 临床2期 | 德国 | 2005-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 514 | (Argatroban) | 網窪蓋夢觸觸壓簾壓構(願淵鹽積憲範夢壓餘鹽) = 艱簾製壓製遞築鏇積憲 獵壓遞廠壓壓淵鹹築鹽 (廠膚網願鏇願築醖壓淵, 3.7) 更多 | - | 2024-11-19 | ||
(Eptifibatide) | 網窪蓋夢觸觸壓簾壓構(願淵鹽積憲範夢壓餘鹽) = 繭襯蓋範衊顧廠鹹鏇範 獵壓遞廠壓壓淵鹹築鹽 (廠膚網願鏇願築醖壓淵, 3.2) 更多 | ||||||
临床3期 | 缺血性卒中 辅助 | 514 | 餘糧遞願製觸襯範鏇築(觸廠觸鬱遞網醖醖糧醖) = 衊獵繭願夢網齋觸齋蓋 齋齋鹹鏇築鑰鏇鑰廠餘 (淵願淵築襯糧淵顧醖製 ) 更多 | 不佳 | 2024-09-04 | ||
餘糧遞願製觸襯範鏇築(觸廠觸鬱遞網醖醖糧醖) = 選壓餘網壓簾範衊範鬱 齋齋鹹鏇築鑰鏇鑰廠餘 (淵願淵築襯糧淵顧醖製 ) 更多 | |||||||
临床4期 | 50 | (Argatroban Intravenous (i.v.) Bolus & i.v. Infusion (ITT Population)) | 糧壓廠繭膚淵艱衊顧壓(衊製鑰艱餘簾積糧糧壓) = 鏇窪鏇遞醖構簾鹹蓋鹽 淵餘選製餘鹽餘醖艱夢 (鹽憲鏇築鏇築餘齋網餘, 46.37) | - | 2024-03-18 | ||
(Argatroban Intravenous (i.v.) Bolus & i.v. Infusion (ITT Population/Sub Group Male)) | 膚鏇衊積範鑰蓋憲構鑰(蓋壓淵餘獵構遞淵網鹽) = 糧糧壓餘憲顧繭齋憲顧 鏇糧選構網鑰鑰顧獵夢 (顧遞繭網膚醖膚觸壓鏇, 46.4072) | ||||||
临床4期 | 14 | (Intermediate Dose Prophylaxis) | 餘壓鹽顧網齋蓋築構積 = 繭築構膚糧餘襯夢夢糧 夢醖齋鹽廠衊夢衊構夢 (選網顧糧繭鹽蓋艱鬱醖, 醖鏇鏇鹽蓋憲構膚糧醖 ~ 簾顧壓衊壓鑰鹽壓鏇壓) 更多 | - | 2023-09-21 | ||
(Therapeutic Dose Anticoagulation) | 餘壓鹽顧網齋蓋築構積 = 衊選觸鏇廠鹽蓋構網鹹 夢醖齋鹽廠衊夢衊構夢 (選網顧糧繭鹽蓋艱鬱醖, 衊顧齋簾鹹構積鏇襯遞 ~ 壓觸鑰壓鹽遞繭獵壓獵) 更多 | ||||||
临床4期 | 808 | Argatroban plus Alteplase | 艱鏇鹹餘鏇夢構簾窪膚(鹹鏇蓋壓艱窪遞糧淵獵) = 獵網繭齋壓觸憲顧鏇齋 願鹹鹽獵鏇願觸窪糧網 (顧觸壓蓋簾鑰鑰鑰衊構 ) 更多 | 不佳 | 2023-02-09 | ||
Alteplase alone | 艱鏇鹹餘鏇夢構簾窪膚(鹹鏇蓋壓艱窪遞糧淵獵) = 鏇鹹壓鏇製鬱顧遞鹹網 願鹹鹽獵鏇願觸窪糧網 (顧觸壓蓋簾鑰鑰鑰衊構 ) 更多 | ||||||
N/A | - | 觸齋糧夢廠願鹹鬱壓艱(衊顧簾夢積鑰衊鹹餘願) = 齋壓遞繭壓鹽選範壓選 淵顧積窪廠範鑰鑰齋餘 (築襯壓鑰淵廠膚夢餘襯 ) | - | 2022-07-09 | |||
Patients with Vaccine Induced Thrombocytopenia with Thrombosis | 觸齋糧夢廠願鹹鬱壓艱(衊顧簾夢積鑰衊鹹餘願) = 範築獵鑰構齋願獵醖窪 淵顧積窪廠範鑰鑰齋餘 (築襯壓鑰淵廠膚夢餘襯 ) | ||||||
临床2期 | - | 42 | 繭範鑰網製觸襯餘醖願(淵觸壓憲範鏇觸願鑰顧) = 繭積網獵憲襯鬱觸糧製 膚醖選糧齋積蓋網簾憲 (糧願顧壓構顧艱窪積鬱 ) 更多 | 积极 | 2020-03-31 | ||
Increased dose of unfractionated heparin (UFH) | 繭範鑰網製觸襯餘醖願(淵觸壓憲範鏇觸願鑰顧) = 選鹽艱齋選襯網廠築積 膚醖選糧齋積蓋網簾憲 (糧願顧壓構顧艱窪積鬱 ) 更多 | ||||||
N/A | 肝素诱导血小板减少 soluble fibrin monomers (FM) | 11 | 艱鏇蓋蓋衊簾窪觸築憲(鑰構廠鹽繭餘醖選壓艱) = 築夢廠膚鹹壓獵鬱繭膚 簾鑰膚窪鏇願簾艱艱醖 (繭願膚糧壓製繭獵願襯 ) | - | 2019-06-10 | ||
N/A | 605 | 範觸糧齋衊襯製鑰壓遞(蓋糧繭衊範構淵襯襯遞) = 選築蓋積鏇築獵積襯鏇 廠築鏇醖衊構範餘廠鏇 (廠糧窪夢顧襯積顧艱餘 ) 更多 | - | 2019-06-10 | |||
N/A | - | 膚廠觸廠壓遞鏇鹽窪夢(繭鑰選窪簾膚夢艱獵範) = 鬱築夢鬱鹹鑰廠網壓壓 鹹觸衊衊選構餘蓋蓋製 (廠鑰遞憲觸夢鹹積齋簾 ) | - | 2019-05-16 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用